Dr. Daniel C. Baumgart,  MD, PhD, MBA, FRCP (London)

BAUMGART-BILD-233x300.jpg

Daniel C. Baumgart, MD PhD MBA FACP FRCP (Lon) AGAF went to medical school in BerlinBasle (Switzerland) and Würzburg (Bavaria). He received his training in internal medicine, gastroenterology, hepatology and immunology at the Charité and as a German Academic Exchange Service (DAAD) and German Research Foundation (DFG) scholar at the University of Pennsylvania, Philadelphia, PA, USA, Georgetown University, Washington, DC, USA, Lombardi Cancer Center, National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) Bethdesda, MD, USA, Inova Fairfax Hospital Fairfax, VA, USA, Virginia Hospital Center, Arlington, VA, USA as well as US Public Health Service und Veterans Affairs Medical Center in Washington, DC, USA. Dr. Baumgart holds an unrestricted license to practice medicine and surgery in the US, Canada and Germany.

Prior to his current appointment as Professor and Director, Division of GastroenterologyAlberta Health Services (AHS) Zone Head for the Edmonton Zone, and Director of the Inflammatory Bowel Disease Unit at the University of Alberta in Edmonton, Canada he served as Professor and Deputy Chief of the Department of Gastroenterology and Hepatology at Charité Medical School of the Humboldt-University of Berlin, Director of the Inflammatory Bowel Disease Center and elected fellow at the Berlin Institute of Health (BIH) endowed by the StiftungCharité foundation. He was Visiting Professor at Yale University, New Haven, CT and Harvard University, Boston, MA, USA.

Dr. Baumgart is actively involved in the development and evaluation of novel diagnostic and therapeutic concepts for Crohn’s disease and ulcerative colitis including new modalities of optical detection to visualize inflammation, mucosal damage and epithelial restitution and image guided intervention. He has been principal investigator in some 200 multinational clinical trials.

A trailblazer of digitization he has a strong interest in evidence based medicine and the application of computers and communication technology in education, research, systems medicine with integration of clinical and scientific data, mathematical modeling of diseases and big data all ultimately aiming to provide precision medicine at the point of care.

His basic science laboratory is focused on the investigation of dendritic cells in innate and adaptive immunity, especially microbial recognition and human microbiome.

Dr. Baumgart has been serving on the editorial boards of leading medical and scientific journals including The Lancet, Gut and Inflammatory Bowel Diseases for more than a decade, elected member of the Cochrane IBD special interest group, elected executive board member of the German IBD Compentence Network within the German Society for Gastroenterology (DGVS) and sits on various other national and international expert, consensus and guideline panels.

A BMW Herbert Quandt Foundation responsible leadership alumnus and passionate educator, Dr. Baumgart developed an innovative integrated clinical and research training curriculum for academic physicians, that received numerous awards including the VolkswagenStiftung foundation's Off the Beaten Track award for its extraordinary design and visionary impetus to academia and has been approved by the German Research Foundation (DFG)Federal Ministry for Education and Research (BMBF), the German Council of Science and Humanities (WR) and adopted by German medical schools nationwide.

In 2013 Dr. Baumgart was appointed fellow, American College of Physicians (FACP), Philadelphia; in 2014 fellow, American Gastroenterological Association (AGAF), Bethesda; and in 2017 Fellow of the Royal College of Physicians (FRCP), London, UK.

 

Dr. Levinus A Dieleman, MD, PhD

 Adapted from Crohn's and colitis UK

Dr. Leo A. Dieleman is Professor of Medicine, clinician-scientist and the Director of IBD Clinical Research at the Division of Gastroenterology.

Dr. Dieleman is originally from the Netherlands, received his MD degree from Catholic University of Nijmegen in 1983, finished his Internal Medicine training at Leiden in 1989, and his clinical GI training at the Free University of Amsterdam in 1996. Between his clinical training he received a Fogarty Fellowship from NIH that formed the basis of his PhD studies on the role of cytokines in experimental and human IBD with Dr. Charles Elson at UAB Birmingham, Alabama and he subsequently received his PhD degree in 1995 at the Free University of msterdam during his clinical GI Fellowship. Dr Dieleman then emigrated to join the GI Division as Assistant Professor in Chapel Hill North Carolina. Under the mentorship of Dr. Balfour Sartor he received a KO8 and RO3 Award from NIH.

Since 2003 Dr Dieleman is at the University of Alberta. Dr. Dieleman is an internationally recognized scientist on the role of intestinal bacteria, probiotics, prebiotics and diets for the pathogenesis and treatment of IBD. He has been continuously funded by NIH, CIHR, Crohn’s and Colitis Foundation of Canada and Alberta Innovates since 1998 and has published over 100 original articles and book chapters in several high ranked journals.

Dr. Brendan P Halloran, MD

 adapted from crohn's and colitis uk

Dr. Brendan P. Halloran is Assistant Professor at the Division of Gastroenterology. He also serves as the Clinical Co-Director of the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) and Co-Director of the Small Bowel Endoscopy Program.

Dr. Halloran’s research interests include improving treatment of IBD patients and health economic assessments of biologic therapies for the treatment of IBD. He is also actively involved in researching application of microarray technology to predict the outcome and a patient's response to biologic therapies as well as role of Epstein-Barr virus in IBD.

Dr. Halloran’s research team is also assessing double-balloon endoscopy as a relatively new technology for the management of patients with Crohn's disease of the small bowel. Imaging of the entire intestinal tract provides insight into how the individual is responding to therapy and can inform treatment modifications.

Dr. Karen Kroeker, MD, MSc, FRCPC

 ADAPTED FROM CROHN'S AND COLITIS UK

Dr. Karen I. Kroeker is an Assistant Professor of Medicine at the University of Alberta. She received her medical doctorate degree from the University of Calgary in 2004. She completed 3 years of internal medicine residency at the University of British Columbia in Vancouver, BC. Following the completion of her gastroenterology residency at the University of Alberta, she completed an Advanced Clinical & Research Fellowship in IBD. She received her Masters of Experimental Medicine at the University of Alberta in 2012.

Dr. Kroeker joined the Faculty of Medicine at the University of Alberta in 2010. She has a large practice of IBD patients and runs a pediatric IBD transition clinic. She is involved with the implementation of the eClinician electronic medical record in the Division of Gastroenterology. Dr. Kroeker is the Director of the IBD Clinic at the University of Alberta. Her research interests include understanding the impact of a pediatric diagnosis of IBD on the psychosocial impact of IBD, adherence to therapy and therapeutic monitoring in IBD, and the role of vitamin D in the treatment of IBD.

Dr. Kroeker is the Gastroenterology Residency Program Director. She is actively involved in the teaching of residents and fellows in gastroenterology and IBD. She is a preceptor in the teaching of medical students through the Physicianship program at the University of Alberta and teaches in the GI Block. 

Dr. Farhad Peerani, MD, FRCPC

Dr. Farhad Peerani is Assistant Professor of Medicine at the University of Alberta. 

Dr. Peerani is an Assistant Professor of Medicine at the University of Alberta. He obtained his medical degree from the University of British Columbia and then completed both his internal medicine residency and gastroenterology fellowship at the University of Alberta. Dr. Peerani then pursued an advanced 2-year clinical research IBD fellowship at both the University of Alberta and Mount Sinai Hospital in New York City. This fellowship was supported by the University of Alberta and the CIHR CAG Fellowship Award.

His research interests include studying the pathophysiology of elderly-onset inflammatory bowel disease (IBD) as well as investigating the safety, efficacy and management of various therapeutic regimens used in ageing IBD patients. Furthermore, he is also interested in better understanding the IBD phenotype in patients with primary sclerosing cholangitis.

Dr. Karen Wong, MD

IMG_2126.JPG

Dr. Karen Wong is Assistant Clinical Professor of Medicine at the University of Alberta. 

She received her medical doctorate degree in the University of Alberta. She then completed internal medicine residency and Fellowship in Gastroenterology at the University of Western Ontario, London, Ontario. She was the first Fellow accepted into the Advanced IBD Fellowship as an Axcan fellow at the University of Alberta.

Dr. Wong's clinical and research interests focus on the management of IBD using fecal microbiota transplantation.

 

To go back to the IBD Unit main page click here